Complications and treatment in patients with COVID-19 with and without GI symptoms
| Variable | GI symptoms (n=74) | No GI symptoms (n=577) | P value |
| Complications | |||
| Acute respiratory distress syndrome | 5/74 (6.76%) | 12/577 (2.08%) | 0.034 |
| Shock | 1/74 (1.35%) | 1/577 (0.17%) | 0.215 |
| Liver injury | 13/74 (17.57%) | 51/577 (8.84%) | 0.035 |
| Treatment | |||
| Anticoronavirus treatment | 66/74 (89.19%) | 480/577 (83.19%) | 0.239 |
| Timing from onset of illness to antiviral therapy | 5 (3–6) | 4 (2–6) | 0.062 |
| Mechanical ventilation | 5/74 (6.76%) | 12/577 (2.08%) | 0.034 |
| CRRT | 0 | 0 | |
| ECMO | 0 | 0 | |
| Glucocorticoids | 11/74 (14.86%) | 63/577 (10.92%) | 0.443 |
| Antibiotic treatment | 31/74 (41.89%) | 246/577 (42.63%) | 0.903 |
| Admission to intensive care unit | 5/74 (6.76%) | 12/577 (2.08%) | 0.034 |
Data are presented as medians (IQR), n (%) and n/N (%).
CRRT, continuous renal replacement therapy; ECMO, extracorporeal membrane oxygenation .